Genetic dissection of behavioural and autonomic effects of Δ9-tetrahydrocannabinol in mice

PLoS Biology

Volumn 5, Issue 10, 2007, Pages 2354-2368

  Monory, Krisztina ^a,b   Blaudzun, Heike ^b   Massa, Federico ^a,b   Kaiser, Nadine ^a   Lemberger, Thomas ^c   Schütz, Günther ^c   Wotjak, Carsten T ^b   Lutz, Beat ^a,b   Marsicano, Giovanni ^a,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; CANNABINOID 1 RECEPTOR; DOPAMINE 1 RECEPTOR; DRONABINOL; GLUTAMIC ACID; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BRAIN CELL; BRAIN NERVE CELL; CELL FUNCTION; CELL POPULATION; CELL SUBPOPULATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENETICS; INTERNEURON; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WILD TYPE; ANIMAL; ANIMAL BEHAVIOR; BODY TEMPERATURE; CATALEPSY; CHEMICALLY INDUCED DISORDER; GENE EXPRESSION; GENE SILENCING; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; NEOCORTEX; NOCICEPTIVE RECEPTOR; PAIN THRESHOLD; PATHOLOGY; PATHOPHYSIOLOGY;

CANNABIS SATIVA; MUS;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR, ANIMAL; BODY TEMPERATURE; CATALEPSY; CORPUS STRIATUM; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION; GENE SILENCING; GLUTAMIC ACID; INTERNEURONS; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEOCORTEX; NOCICEPTORS; PAIN THRESHOLD; PSYCHOTROPIC DRUGS; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 35649000942     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.0050269     Document Type: Article

References (82)

1. Mechoulam R, Hanus L (2000) A historical overview of chemical research on cannabinoids. Chem Phys Lipids 108: 1-13.
2. Zuardi AW (2006) History of cannabis as a medicine: A review. Rev Bras Psiquiatr 28: 153-157.
3. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202.
4. Martin BR, Compton DR, Little PJ, Martin TJ, Beardsley PM (1987) Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids. NIDA Res Monogr 79: 108-122.
5. Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, et al. (2005) {Delta}9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther 314: 329-337.
6. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96: 5780-5785.
7. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
8. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, et al. (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
9. Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277: 586-594.
10. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, et al. (2001) Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322-328.
11. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 299-325.
12. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100.
13. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
14. Di Marzo V, Bifulco M, De Petrocellis L. (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784.
15. Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
16. Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29: 37-76.
17. Marsicano G, Lutz B (2006) Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 29: 27-46.
18. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46: 101-122.
19. Walker JM, Hohmann AG (2005) Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol: 509-554.
20. Massa F, Storr M, Lutz B (2005) The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 83: 944-954.
21. Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785.
22. Breivogel CS, Childers SR (1998) The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5: 417-431.
23. Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83: 1017-1066.
24. Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213-4225.
25. Matsuda LA, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327: 535-550.
26. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88.
27. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, et al. (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455-466.
28. Takahashi KA, Castillo PE (2006) The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 139: 795-802.
29. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, et al. (2006) Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 26: 5794-5799.
30. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, et al. (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26: 2991-3001.
31. Morozov A, Kellendonk C, Simpson E, Tronche F (2003) Using conditional mutagenesis to study the brain. Biol Psychiatry 54: 1125-1133.
32. Branda CS, Dymecki SM (2004) Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6: 7-28.
33. Sola C, Tusell JM, Serratosa J (1999) Comparative study of the distribution of calmodulin kinase II and calcineurin in the mouse brain. J Neurosci Res 57: 651-662.
34. Burgin KE, Waxham MN, Rickling S, Westgate SA, Mobley WC, et al. (1990) In situ hybridization histochemistry of Ca2+/calmodulin-dependent protein kinase in developing rat brain. J Neurosci 10: 1788-1798.
35. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
36. Lemberger T, Parlato R, Dassesse D, Westphal M, Casanova E, et al. (2007) Expression of Cre recombinase in dopaminoceptive neurons. BMC Neurosci 8: 4.
37. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, et al. (2002) Disruption of CREB function in brain leads to neurodegeneration. Nat Genet 31: 47-54.
38. Hohmann AG, Herkenham M (2000) Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: A double-label in situ hybridization study. Synapse 37: 71-80.
39. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, et al. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432.
40. Le Moine C., Bloch B (1995) D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 355: 418-426.
41. Aizman O, Brismar H, Uhlen P, Zettergren E, Levey AI, et al. (2000) Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci 3: 226-230.
42. van der Stelt M, Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480: 133-150.
43. Gerdeman GL, Lovinger DM (2003) Emerging roles for endocannabinoids in long-term synaptic plasticity. Br J Pharmacol 140: 781-789.
44. Casanova E, Fehsenfeld S, Mantamadiotis T, Lemberger T, Greiner E, et al. (2001) A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 31: 37-42.
45. Goebbels S, Bormuth I, Bode U, Hermanson O, Schwab MH, et al. (2006) Genetic targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice. Genesis 44: 611-621.
46. Rawls SM, Cowan A, Tallarida RJ, Geller EB, Adler MW (2002) N-methyl-Daspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4- morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6 H-pyrrolo[3,2,1-i,j]quinolin-6- one], a cannabinoid agonist, interact to produce synergistic hypothermia. J Pharmacol Exp Ther 303: 395-402.
47. Salmi P (1998) Independent roles of dopamine D1 and D2/3 receptors in rat thermoregulation. Brain Res 781: 188-193.
48. Canini F, Bourdon L (1998) Dopamine involvement in thermoregulatory responses to heat in rats. Neurosci Lett 241: 91-94.
49. Nava F, Carta G, Gessa GL (2000) Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-tetrahydrocannabinol in rats. Pharmacol Biochem Behav 66: 183-187.
50. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393-411.
51. Alger BE (2006) Not too excited? Thank your endocannabinoids. Neuron 51: 393-395.
52. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, et al. (2007) Hardwiring the brain: Endocannabinoids shape neuronal connectivity. Science 316: 1212-1216.
53. Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001) Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. Journal of Neuroscience 21: 109-116.
54. Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85: 468-471.
55. Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, et al. (2003) Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10: 116-128.
56. Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445: 643-647.
57. Gerfen CR (1989) The neostriatal mosaic: striatal patch-matrix organization is related to cortical lamination. Science 246: 385-388.
58. Beloozerova IN, Sirota MG, Swadlow HA (2003) Activity of different classes of neurons of the motor cortex during locomotion. J Neurosci 23: 1087-1097.
59. Sirota MG, Swadlow HA, Beloozerova IN (2005) Three channels of corticothalamic communication during locomotion. J Neurosci 25: 5915-5925.
60. Rawls SM, Cabassa J, Geller EB, Adler MW (2002) CB(1) receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4- morpholinylmethyl)-1-(1-naphthalenyl- carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6- one]-induced hypothermia. J Pharmacol Exp Ther 301: 963-968.
61. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Ogata A, et al. (2007) Delta(9)-tetrahydrocannabinol (Delta(9)-THC) prevents cerebral infarction via hypothalamic-independent hypothermia. Life Sci 80: 1466-1471.
62. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, et al. (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
63. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198-12203.
64. Lever IJ, Rice AS (2007) Cannabinoids and pain. Handb Exp Pharmacol 265-306.
65. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, et al. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 10: 870-879.
66. Lichtman AH, Martin BR (1991) Cannabinoid-induced antinociception is mediated by a spinal alpha 2-noradrenergic mechanism. Brain Res 559: 309-314.
67. Braun AR, Laruelle M, Mouradian MM (1997) Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J Neural Transm 104: 341-362.
68. Wadenberg ML (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20: 325-339.
69. Del Bel EA, Guimaraes FS, Bermudez-Echeverry M, Gomes MZ, Schiaveto-de-souza A, et al. (2005) Role of nitric oxide on motor behavior. Cell Mol Neurobiol 25: 371-392.
70. Kataoka Y, Ohta H, Fujiwara M, Oishi R, Ueki S (1987) Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol. Neuropharmacology 26: 55-60.
71. Egashira N, Matsuda T, Koushi E, Mishima K, Iwasaki K, et al. (2006) Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol- induced catalepsy-like immobilization in mice. Eur J Pharmacol 550: 117-122.
72. Häring M, Marsicano G, Lutz B, Monory K (2007) Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146: 1212-1219.
73. Oropeza VC, Mackie K, Van Bockstaele EJ (2007) Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 1127: 36-44.
74. Lichtman AH, Varvel SA, Martin BR (2002) Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66: 269-285.
75. Wotjak CT (2005) Role of endogenous cannabinoids in cognition and emotionality. Mini Rev Med Chem 5: 659-670.
76. Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29: 225-232.
77. Tappe-Theodor A, Agarwal N, Katona I, Rubino T, Martini L, et al. (2007) A molecular basis of analgesic tolerance to cannabinoids. J Neurosci 27: 4165-4177.
78. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2005) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67: 1697-1704.
79. Rios C, Gomes I, Devi LA (2006) mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387-395.
80. Mackie K (2005) Cannabinoid receptor homo- and heterodimerization. Life Sci 77: 1667-1673.
81. Azad SC, Marsicano G, Eberlein I, Putzke J, Zieglgansberger W, et al. (2001) Differential role of the nitric oxide pathway on delta(9)-THC-induced central nervous system effects in the mouse. Eur J Neurosci 13: 561-568.
82. Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 451-460.